Press Release Archive
-
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
-
Johnson & Johnson Vision Showcases Latest Clinical Data and Eye Care Solutions at the ESCRS 2018 Annual Meeting
-
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
-
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
-
European Commission expands labelling for Janssen’s INVOKANA® and VOKANAMET® to include positive data on cardiovascular outcomes
-
Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants
-
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
-
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant DepressionJanssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
-
Johnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare ConferenceJohnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference
-
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood CancerU.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer